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Abstract: Obese sheep were used to assess the effects of palmitoleic (C16:1 cis-9) acid infusion 
on lipogenesis and circulating insulin levels. Infusion of 10 mg/kg body weight (BW)/day C16:1 
intravenously in obese sheep reduced (P,0.01) weight gain by 77%. Serum palmitoleic levels 
increased (P,0.05) in a linear manner with increasing levels of C16:1 infusion. Cis-11 vaccenic 
(C18:1 cis-11) acid, a known elongation product of palmitoleic acid, was also elevated (P,0.05) 
in serum after 14 days and 21 days of infusion. Plasma insulin levels were lower (P,0.05) (10 mg/
kg BW/day C16:1) than controls (0 mg/kg BW/day C16:1) at 14 days and 28 days of infusion. 
Infusion of C16:1 resulted in linear increases in tissue concentrations of palmitoleic, cis-11 
vaccenic, eicosapentaenoic, and docosapentaenoic acids in a dose-dependent manner. Total lipid 
content of the semitendinosus (ST) muscle and mesenteric adipose tissue was reduced (P,0.01) 
in both 5 mg/kg and 10 mg/kg BW C16:1 dose levels. Total lipid content and mean adipocyte 
size in the longissimus muscle was reduced (P,0.05) in the 10 mg/kg BW C16:1 dose level 
only, whereas total lipid content and adipocyte size of the subcutaneous adipose tissue was not 
altered. Total lipid content of the liver was also unchanged with C16:1 infusion. Palmitoleic acid 
infusion upregulated (P,0.05) acetyl-CoA carboxylase (ACC), fatty acid elongase-6 (ELOVL6), 
and Protein kinase, AMP-activated, alpha 1 catalytic subunit, transcript variant 1 (AMPK) mRNA 
expressions in liver, subcutaneous adipose, and ST muscle compared to the controls. However, 
mRNA expression of glucose transporter type 4 (GLUT4) and carnitine palmitoyltransferase 
1b (CPT1B) differed between tissues. In the subcutaneous adipose and liver, C16:1 infusion 
upregulated (P,0.05) GLUT4 and CPT1B, whereas these genes were downregulated (P,0.05) 
in ST muscle with C16:1 infusion. These results show that C16:1 infusion for 28 days reduced 
weight gain, intramuscular adipocyte size and total lipid content, and circulating insulin levels. 
These changes appear to be mediated through alterations in expression of genes regulating 
glucose uptake and fatty acid oxidation specifically in the muscles.
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Introduction
Palmitoleic (C16:1 cis-9) acid is a unique monounsaturated fatty acid that is pro-
duced almost exclusively through desaturation of palmitic acid via stearoyl-CoA 
desaturase-1 (SCD1). Dietary sources of palmitoleic acid are very limited with natural 
sources being macadamia oil and sea buckthorn oil, which contain about 19%–28% 
of palmitoleic acid. Palmitoleic acid has recently been named a lipokine that regulates 
lipogenesis and coordinates systemic metabolism.1 These researchers found that infus-
ing tripalmitolein versus tripalmitin for 6 hours into dietary-induced obese mice with 
homozygous mutations for fatty acid binding proteins (aP2, mal1) decreased SCD1, 
fatty acid synthase (FASN), and fatty acid elongase-6 (ELOVL6) expression in the 





liver compared to control. In addition, Cao et al1 suggest 
that palmitoleic acid acts as an insulin-sensitizing hormone 
that improves glucose metabolism. Knockout of SCD1 in 
mice reduces adipose tissue deposition, increases insulin 
sensitivity, and makes animals resistant to diet-induced 
weight gain.2 In our laboratory, exogenous administration of 
palmitoleic acid to bovine adipocytes in vitro downregulates 
de novo lipogenesis and upregulates fatty acid oxidation to 
direct fatty acids toward energy expenditure and away from 
storage.3,4 The objective of this experiment was to assess 
the effects of palmitoleic (C16:1) acid infusion at varying 




Southdown sheep (n=15; 95 kg body weight [BW]) were 
used to assess the effects of palmitoleic (C16:1 cis-9) acid 
infusion on lipogenesis and circulating insulin levels in obese 
sheep. Omega-7 enriched oil (Provinal™; Tersus Pharma-
ceuticals) was infused, twice daily for 28 days via indwelling 
jugular catheter, at three levels of palmitoleic acid: 0 mg 
C16:1/kg BW/d, 5 mg C16:1/kg BW/d, or 10 mg C16:1/kg 
BW/d. Provinal™ is an omega-7 enhanced oil with 50% of 
total fatty acids as palmitoleic acid and less than 2.5% as 
palmitic acid. The oil was solubilized in 40% ethanol and 
immediately injected into the catheter at 8 am and 4 pm 
for each lamb. All lambs received the same amount of 40% 
ethanol per dose regardless of the oil level. A 16-gauge 
indwelling jugular catheter (Abbocath; Abbott Laborato-
ries, Abbott Park, IL, USA) was inserted and sutured to the 
skin 1 day prior to initiation of experiment for substrate 
administration and blood sampling. Catheters were kept 
patent with 4% sodium citrate in sterile saline (Jorgensen 
Laboratories, Inc., Loveland, CO, USA). On days 0, 7, 14, 
and 21, blood samples were obtained from each lamb at 5 
minutes postinfusion. Whole blood was placed into serum 
and heparinized vacuum tubes, and processed according to 
Long et al.5
Lambs were fed at National Research Council6 rec-
ommendations and divided into three pens with equal 
representation of treatments per pen. At 28 days, lambs 
were slaughtered. Live weight was also collected on a 
weekly basis, and average daily gain was calculated. At 
slaughter, weights of kidney, omental and mesenteric adi-
pose tissues, as well as hot carcass weight were collected. 
Samples of subcutaneous adipose tissue at the 12th rib, 
 semitendinosus (ST) muscle, and liver were collected at 
slaughter and immediately frozen in liquid nitrogen for 
storage at −80°C until subsequent RNA extraction. At 
24 hours postmortem, carcass data were collected and 
samples obtained from subcutaneous and intramuscular 
adipose tissues of the longissimus muscle for cell size 
determination. Samples of subcutaneous adipose, mesen-
teric adipose, longissimus muscle, ST muscle, and liver 
were collected for total lipid and fatty acid composition. 
One side of each carcass from 0 mg C16:1/kg BW/d and 
10 mg C16:1/kg BW/d treatments was used to assess 
body composition analyses by physical dissection and 
proximate analyses.
glucose and insulin
Glucose and insulin levels were measured as described by 
Long and Schafer.7
Proximate analyses
Dissected muscle and adipose tissues for body compo-
sition analyses were ground and mixed, and samples 
were obtained for proximate analyses according to 
Duckett et al.8
adipocyte size and distribution
Adipose tissue samples were collected from intramuscular 
(dissected from longissimus muscle at the 12th rib) and 
subcutaneous (at the 12th rib) depots for determination of 
adipocyte cell size according to Etherton et al.9  Adipocytes 
were counted and sized using a particle sizing and counting 
analyzer (Multisizer 4 Coulter Counter; Beckman Coulter 
Inc., Brea, CA, USA).
lipids
Adipose, muscle samples, and liver were frozen, lyophilized, 
and ground in a food processor. Serum samples (1 mL) were 
also lyophilized. Total fat content and fatty acid composi-
tion were determined according to Duckett et al.8
For determination of lipid fractions, total lipids were 
extracted from ST muscle samples via Folch et al10 method. 
The neutral lipid, phospholipid (PhL), and free fatty acid 
(FFA) fractions were separated according to Ruiz et al.11 
Each fraction was then dried under nitrogen, transmethy-
lated, and analyzed by gas chromatography according to 
Duckett et al.8
rna isolation
RNA was extracted from subcutaneous adipose tissues, ST 
muscles, and liver as described in Duckett et al.12
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Quantitative Pcr
Primers were designed using Primer3 software (http://
primer3plus.com/) and are reported in Table 1. qPCR was 
conducted according to Duckett et al12 using glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) as the housekeeping 
gene. Normalized delta CT values were calculated for each 
sample and analyzed as described in the Statistical analyses 
section.
Western blots
Proteins were extracted from liver, ST, and subcutaneous 
adipose tissues of control (0 mg/kg BW C16:1) and high 
(10 mg/kg BW C16:1) levels using T-PER solution containing 
Halt Phosphatase Inhibitor according to the manufacturers’ 
recommendations. Protein concentrations were measured 
using Bradford method (Pierce Coomassie; Thermo Fisher 
Scientific, Waltham, MA, USA). Equal amounts of pro-
tein were diluted in sample reducing buffer containing 
5% β-mercaptoethanol and heated at 95°C for 5 minutes. Pro-
teins were separated using 12%  polyacrylamide gels at 60 V 
for 30 minutes. Blotting of protein was performed on polyvi-
nylidene difluoride membranes using a Trans-Blot (BioRad) 
apparatus at 350 mA for 1 hour at 4°C. Membranes were 
blocked with 5% fat-free milk in 0.1% Tween-20 phosphate 
buffered saline (PBS-Tween) at room temperature.  Primary 
antibodies for AMPKα1 (PA1-2109, 1:5,000; Thermo Fisher 
Scientific) and p-AMPKα1  (PA5-17831, 1:1,000; Thermo 
Fisher Scientific) were incubated overnight at 4°C. Blots 
were washed with PBS several times and then incubated 
with secondary antibody (goat anti-rabbit  IgG-HRP, 1:6,000 
and 1:2,000; Thermo Fisher Scientific) for 1 hour at room 
 temperature. Blots were washed with PBS several times and 
then SuperSignal West Femto substrate (34095; Thermo 
Fisher Scientific) was added for 5 minutes. Chemilumi-
nescence was detected using an Alpha Innotech Imager 
(ProteinSimple, Santa Clara, CA, USA). Density of the bands 
was quantified using the Alpha Innotech software.
Statistical analyses
Data were analyzed in a completely randomized design 
using general linear models (GLM) procedures of SAS (SAS 
Institute Inc., Cary, NC, USA) with palmitoleic acid dose 
level, tissue, and two-way interaction in the model. For 
serum data, palmitoleic acid dose level, time for experi-
ment, and the two-way interaction were included in the 
model. Orthogonal contrasts were used to assess linear 
or quadratic changes in variables because of dose level 
of palmitoleic acid infusion. For gene expression, delta CT 
values were analyzed using GLIMMIX procedure with treat-
ment, tissue, and two-way interaction in the model. Gene 
expression levels were calculated using the ∆∆C
T
 methods13 
and are presented as fold-change in gene expression for 
experiment (10 mg/kg lipid weight (LW)/d C16:1) versus 
controls (0 mg C16:1/kg LW/d).
Results
Infusion of 10 mg/kg BW/d palmitoleic (C16:1 cis-9) acid 
intravenously in obese sheep reduced (P,0.01) weight gain 
Table 1 Primer sequences (5′–3′) for quantitative real-time Pcr
Gene abbreviations Forward Reverse Efficiency
ACC gcTgcTggTgTTccTaaagc gTccTcaaaTTgTgcgTgaa 1.01
AKT1 aagaggcaggaggaggagac cccagcagcTTcaggTacTc 1.01
AMPK gTcaaagTcggccaaaTgaT ccTccgaacacgcaaaTaaT 1.03
CPT1a ccaccTcTTcTgccTcTacg TTgaacagTTccaccTgcTg 1.04
CPT1b ggTcgacTTccagcTcagTc caggaggaacccacTgTTgT 1.05
ELOVL5 cgccacacTTaacagcTTca agcTggTcTggaTgaTggTc 1.10
ELOVL6 agTggaTgcaggaaaacTgg aagggTcagagaccagagca 1.05
FABP4 aaTTgggccaggaaTTTgaT gcaccagcTTaTcaTccaca 1.00
FASN TcaTcccccTgaTgaagaag gcagTggTccaccaggTagT 1.09
GAPDH gggTcaTcaTcTcTgcaccT ggTcaTaagTcccTccacga 1.01
GLUT4 cTcTccacTTgcccagagac cTgccTagccacaacacaaa 1.04
HSL ggcacTccTggaTgcTgaTT cacTgTccgcggagaTacTc 0.98
IR cTgacTTccgagaccTccTg gTTcTgTgacTTggggTcgT 0.95
IRS TccgccTTTccTcaagTTcc agcTgTgTccaccTTTcgag 0.99
PI3KR1 aagTcaTggccaTTgTaggc accTcTTgcTcTTgcggTaa 0.96
SCD1 cgacgTggcTTTTTcTTcTc gaTgaagcacaacagcagga 0.96
Abbreviations: Pcr, polymerase chain reaction; acc, acetyl-coa carboxylase; aKT1, v-akt murine thymoma viral oncogene homolog 1; aMPK, protein kinase, aMP-activated, 
alpha 1 catalytic subunit, transcript variant 1; cPT1a, carnitine palmitoyltransferase 1a; cPT1b, carnitine palmitoyltransferase 1b; elOVl5, fatty acid elongase-5; elOVl6, fatty acid 
elongase-6; FaBP4, fatty acid binding protein 4; FaSn, fatty acid synthase; gaPDh, glyceraldehyde-3-phosphate dehydrogenase; glUT4, glucose transporter type 4; hSl, hormone-
sensitive lipase; ir, insulin receptor; irS, insulin receptor substrate; Pi3Kr1, phosphoinositide-3-kinase, regulatory subunit 1 (alpha); ScD1, stearoyl-coa desaturase-1.





Table 2 gain, carcass traits, and body composition of lambs infused with varying levels of palmitoleic (c16:1) acid
mg C16:1/kg LW/d SEM Contrasts
0 5 10 Linear Quadratic
Daily weight gain, kg/d 0.30 0.29 0.07 0.051 0.01 0.18
carcass weight, kg 58.82 56.68 56.18 2.02 0.38 0.75
ribeye area, cm2 22.3 22.4 20.3 1.29 0.31 0.48
Fat thickness, cm 1.98 1.93 1.93 0.25 0.88 0.94
Body wall thickness, cm 4.72 4.98 4.93 0.37 0.70 0.74
Visceral fat depots, kg
 Perirenal fat 2.30 2.15 2.41 0.29 0.78 0.58
 Omental fat 2.57 3.16 2.68 0.37 0.83 0.26
 Mesenteric fat 0.99 0.87 0.83 0.073 0.15 0.67
Body composition, % of carcass weight
 Moisture 31.49 – 30.54 0.90 0.48 –
 lipid 39.18 – 40.44 2.25 0.70 –
 Protein 14.94 – 14.58 0.78 0.75 –
 Bone 14.39 – 14.43 1.09 0.98 –
Note: –, not measured. 
Abbreviations: lW, lipid weight; d, days; SeM, standard error of the mean.
Table 3 Serum fatty acid content from lambs infused with varying levels of palmitoleic (c16:1) acid
Fatty acids, μg/mL mg C16:1/kg LW/d SEM Contrasts
0 5 10 Linear Quadratic
c14:0 3.47 3.28 3.35 0.17 0.62 0.55
c14:1 3.93 3.68 3.30 0.26 0.09 0.84
c16:0 107.94 102.68 110.53 5.72 0.75 0.35
c16:1 cis-9 8.93 11.69 14.28 1.16 0.001 0.95
c18:0 150.92 124.35 154.18 9.50 0.81 0.02
c18:1 trans 13.00 16.21 15.66 1.30 0.15 0.24
c18:1 cis-9 147.07 132.18 151.00 9.04 0.76 0.13
c18:1 cis-11 5.05 5.89 7.66 0.39 0.001 0.32
c18:2 cis-9,12 201.21 198.33 236.55 13.71 0.07 0.22
c18:3 cis-9,12,15 7.15 7.29 9.69 1.12 0.11 0.41
c20:4 cis-5,8,11,14 28.73 28.15 38.58 2.00 0.001 0.02
c20:5 cis-5,8,11,14,17 3.78 4.16 4.94 0.27 0.001 0.56
c22:5 cis-7,10,13,16,19 8.76 8.12 9.22 0.49 0.51 0.15
c22:6 cis-4,7,10,13,16,19 8.69 9.17 9.02 0.64 0.71 0.38
Total, μg/ml 757.60 716.29 837.11 43.45 0.22 0.10
Saturated 262.33 230.31 268.06 15.13 0.79 0.06
Monounsaturated 12.86 15.37 17.58 1.26 0.01 0.92
Polyunsaturated n-6 229.94 226.48 275.13 14.95 0.04 0.16
Polyunsaturated n-3 28.38 27.74 32.87 2.09 0.13 0.26
ratio n-6:n-3 8.43 8.77 8.98 0.41 0.34 0.90
c16:1–c16:0 0.083 0.12 0.13 0.01 0.001 0.48
c18:1–c18:0 0.99 1.12 0.99 0.04 0.86 0.01
c16:1–c18:1c11 0.83 1.06 0.98 0.11 0.35 0.28
Abbreviations: lW, lipid weight; d, days; SeM, standard error of the mean.
by 77% (Table 2). Carcass traits, visceral adipose depots, and 
body composition were not altered (P.0.05) by palmitoleic 
acid infusion for 28 days. The lambs from this experiment 
averaged 1.95 cm of fat thickness with a body composition of 
40% of total lipid, which would be considered obese. Sheep are 
more similar to humans in fat distribution patterns than other 
animal models. Sheep deposit more fat within the abdominal 
cavity (about 33% of total fat) than pigs or rodents.13
Serum palmitoleic (C16:1 cis-9) levels increased (P,0.05) 
in a linear manner with increasing levels of palmitoleic acid 
infusion when sampled at 5 minutes postinfusion (Table 3). 
In addition, palmitoleic acid infusion increased (P,0.001) 
arachidonic (C20:4) and eicosapentaenoic (C20:5) acid con-
tents in the serum in a linear manner. Myristoleic (C14:1) and 
linoleic (C18:2) acid contents in the serum tended (P,0.10) to 
be increased in a linear manner with palmitoleic acid infusion. 
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These changes in individual serum fatty acid content resulted 
in linear (P,0.05) increases in total monounsaturated and 
polyunsaturated n-6 content in the serum. The ratio of palmi-
toleic to palmitic acid in the serum was linearly (P,0.001) 
increased in the sheep infused with palmitoleic acid. The ratio 
of oleic (C18:1 cis-9) to stearic (C18:0) acid was increased 
(P,0.01) in a quadratic  manner. All interactions between 
treatment and days of treatment were nonsignificant except 
for cis-11 vaccenic acid. Cis-11 vaccenic (C18:1 cis-11) acid, 
a known elongation product of palmitoleic acid,3,4 was also 
elevated (P,0.05) in serum after 14 days and 21 days of the 
experiment (Figure 1).
Plasma insulin levels were higher (P,0.05) in the 
10 mg/kg BW/d C16:1 treatment than controls at the start 
of the experiment (Figure 2A). However, after 14 days 
and 28 days on treatment, insulin concentrations were 
lower (P,0.05) for 10 mg/kg BW/d C16:1 than controls 
(0 mg/kg BW). For the 5 mg/kg LW/d C16:1 dose level, 
circulating insulin levels were similar to controls at days 
0 and 14 but were intermediate at day 28. Plasma glucose 
levels were unchanged with palmitoleic acid infusion and 
averaged 95±19.0 mg/dL. There was a treatment by time 
interaction (P,0.05) for Homeostatis Model Assessment-
Insulin Resistance (HOMA-IR) level. HOMA-IR levels 
decreased (P,0.05) over time in 5 mg/kg LW/d and 10 mg/
kg LW/d treatments compared to control, which did not 
change (P.0.05) over time (Figure 2B). Homeostatis Model 
Assessment-beta cell function (HOMA-B) and Homeostatis 
Model Assessment-insulin sensitivity (HOMA-S) values did 
not differ between palmitoleic acid treatment levels.
The fatty acid concentration of longissimus muscle, 






























Figure 1 effects of palmitoleic acid infusion on serum cis-11 vaccenic acid levels.
Notes: changes in serum cis-11 vaccenic (c18:1 cis-11) acid concentration (μg/ml) 
by palmitoleic acid infusion level (0 mg/kg lW/d, 5 mg/kg lW/d, or 10 mg/kg lW/d) 
at 5 minutes post-dosing by time of the experiment.
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Figure 2 changes in plasma insulin concentration and hOMa-ir values with 
palmitoleic acid infusion at three levels.
Notes: Plasma insulin concentrations (μiU/ml) (A) and hOMa-ir (B) in lambs 
infused with varying levels of palmitoleic (c16:1) acid levels (0 mg/kg lW/d, 5 mg/kg 
lW/d, or 10 mg/kg lW/d) by day of experiment.
Abbreviations: lW, lipid weight; d, days; hOMa-ir, homeostatis Model assessment- 
insulin resistance.
liver tissues is shown in Table 4. There were no interactions 
(P.0.05) between treatment and tissue, and the data are 
presented as the average fatty acid concentration for that 
treatment across all tissues. Palmitoleic, cis-11 vaccenic, 
eicosapentaenoic, and docosapentaenoic acid concentra-
tions increased in a linear manner (P,0.05) with increasing 
level of palmitoleic acid infusion. Myristic (C14:1), palmi-
toleic, trans-octadecenoic, and margaric acid concentrations 
increased (P,0.05) in a quadratic manner with palmitoleic 
acid infusion level. Stearic (C18:0) acid decreased (P,0.05) 
in a quadratic manner with palmitoleic acid infusion level. 
Concentrations of total polyunsaturated n-6 and n-3 fatty acids 
were increased in a linear manner (P,0.05) with palmitoleic 
acid infusion. Saturated and odd-chain fatty acid concentra-
tions were increased in a quadratic manner (P,0.05) with 
palmitoleic acid infusion. Other fatty acid concentrations were 
not altered by palmitoleic acid infusion. The ratio of palmito-
leic to palmitic acid was linearly increased, whereas the ratio 





of oleic to stearic acid was quadratically increased (P,0.01) 
with palmitoleic acid infusion. The ratio of palmitoleic acid 
to cis-11 vaccenic acid also increased in a linear and quadratic 
manner (P,0.001) with palmitoleic acid infusion.
Total lipid content of the longissimus muscle, ST muscle, 
and liver is shown in Figure 3A, and subcutaneous and 
mesenteric adipose tissues is shown in Figure 3B. Total 
lipid content of the ST muscle and mesenteric adipose tis-
sue was reduced (P,0.01) in both 5 mg/kg BW C16:1 and 
10 mg/kg BW C16:1 dose levels. Total lipid content of the 
longissimus muscle was reduced (P,0.05) in the 10 mg/kg 
BW C16:1 dose level only. The total lipid content of the 
liver and subcutaneous adipose tissues was not altered 
(P.0.05) with C16:1 infusion. In order to determine if the 
palmitoleic acid and its elongation product, cis-11 vaccenic 
acid, were partitioned into PhL or triacylglyceride fraction, 
lipid separation was conducted on the ST muscle samples. 
Results showed that 94% of the total palmitoleic acid in the 
muscle was present in the neutral (triacylglyceride) fraction 
with only about 3% present as FFA or PhL, regardless of 
treatment. For cis-11 vaccenic acid, it was also predominately 
(90%) located in the neutral lipid fraction with only 2% and 
7% as FFAs or PhL, respectively, regardless of treatment. 
Mean adipocyte size was reduced (P,0.05) in intramuscular 
adipocytes from the longissimus muscle for 10 mg/kg BW 
C16:1 group compared to controls (Figure 4A). Adipocyte 
distribution showed a reduction (P,0.05) in the amount of 
90–140 μm-sized adipocytes and an increase (P,0.05) in the 
amount of 20–80 μm-sized intramuscular adipocytes for the 
10 mg/kg LW/d palmitoleic acid-treated group compared to 
controls (Figure 4B). Mean adipocyte size was not altered 
(P.0.05) in subcutaneous adipose tissues. These results 
show that palmitoleic acid infusion for 28 days reduced 
intramuscular lipid content of the longissimus and ST muscle 
with increasing levels of palmitoleic acid infusion. These 
reductions appear to be because of reductions in intramus-
cular triglyceride content and adipocyte size.
Changes in lipogenic gene expression for subcutaneous 
adipose, ST muscle, and liver with palmitoleic acid infusion 
are shown in Figure 5. Palmitoleic acid infusion upregulated 
(P,0.05) acetyl-CoA carboxylase (ACC) and ELOVL6 
mRNA expression. Expression of other genes involved in 
lipogenesis (FASN, fatty acid elongase-5 [ELOVL5], and 
carnitine palmitoyltransferase 1a [CPT1A]) was unchanged 
(P.0.05) with palmitoleic acid infusion. Palmitoleic acid 
infusion upregulated (P,0.05) protein kinase, AMP-activated, 
alpha 1 catalytic subunit, transcript variant 1 (AMPK) mRNA 
expression in all three tissues (liver, subcutaneous adipose, and 
Table 4 Fatty acid composition of tissues (subcutaneous adipose tissue, mesenteric adipose tissue, liver, longissimus muscle, ST 
muscle) from lambs infused with varying levels of palmitoleic (c16:1) acid
Fatty acid, % of total mg C16:1/kg LW/d SEM Contrasts
0 5 10 Linear Quadratic
c14:0 1.50 1.68 1.45 0.04 0.35 0.001
c15:0 0.31 0.36 0.35 0.03 0.32 0.29
c16:0 20.74 21.35 20.08 0.28 0.11 0.01
c16:1 cis-9 0.89 1.13 1.02 0.04 0.04 0.01
c17:0 1.31 1.43 1.31 0.04 0.96 0.01
c18:0 26.01 23.15 25.09 0.45 0.16 0.001
c18:1 trans 2.69 3.87 3.24 0.26 0.15 0.01
c18:1 cis-9 33.71 33.68 33.24 0.39 0.41 0.67
c18:2 cis-9,12 4.22 4.40 4.63 0.15 0.06 0.91
c18:3 cis-9,12,15 0.45 0.48 0.54 0.02 0.02 0.57
c20:4 cis-5,8,11,14 2.76 2.68 2.88 0.12 0.52 0.40
c20:5 cis-5,8,11,14,17 0.14 0.22 0.31 0.041 0.001 0.90
c22:5 cis-7,10,13,16,19 0.90 0.92 1.09 0.061 0.03 0.35
c22:6 cis-4,7,10,13,16,19 1.05 1.11 1.24 0.11 0.25 0.81
Saturated fatty acids, % 48.25 46.18 46.62 0.52 0.03 0.05
Odd chain fatty acids, % 1.62 1.79 1.66 0.05 0.60 0.01
Monounsaturated fatty acids, % 34.60 34.81 34.27 0.40 0.57 0.45
Polyunsaturated fatty acids, n-6, % 6.42 6.55 6.93 0.16 0.04 0.55
Polyunsaturated fatty acids, n-3, % 2.12 2.26 2.65 0.10 0.001 0.38
ratio, n-6:n-3 4.06 4.53 3.97 0.25 0.79 0.09
c16:1–c16:0 ratio 0.046 0.057 0.057 0.003 0.01 0.11
c18:1–c18:0 ratio 1.53 1.71 1.55 0.047 0.69 0.01
c16:1–c18:1c11 ratio 1.42 1.84 1.73 0.072 0.001 0.001
Abbreviations: ST, semitendinosus; lW, lipid weight; d, days; SeM, standard error of the mean.
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and carnitine palmitoyltransferase 1b (CPT1BI) (Figure 7). In 
the subcutaneous adipose and liver tissues, palmitoleic acid 
infusion upregulated (P,0.05) GLUT4, and CPT1B, whereas 
these genes were downregulated (P,0.05) with palmitoleic 
acid infusion in ST muscle.
Discussion
Infusion of palmitoleic acid increased serum palmitoleic acid 
levels in a dose-dependent manner. Previous research has 
shown that infusion of palmitoleic acid results in immediate 
uptake of the fatty acid into circulation.5 In addition, cis-11 
vaccenic (C18:1 cis-11) acid also increased with palmitoleic 
acid infusion over time. Based on the results, it took about 14 
days of continuous palmitoleic acid infusion for cis-11 vac-
cenic acid to increase in serum above controls in palmitoleic 
acid-infused lambs. Using stable isotopes in vitro, Burns et al3 
confirmed that cis-11 vaccenic acid is an elongation product 
of palmitoleic acid. ELOVL6 is involved with elongation 
of saturated fatty acids of 12–18 carbon length but cannot 
elongate past C18.14 ELOVL5 appears to be involved in elon-














































Figure 3 effects of palmitoleic acid infusion on intramuscular lipid content.
Notes: Total lipid content (g/100 g of tissue) of liver, lM, and ST muscle (A), and 
SQ and MS fat (B) in lambs infused with varying levels of palmitoleic (c16:1) acid 
levels (0 mg/kg lW/d, 5 mg/kg lW/d, or 10 mg/kg lW/d) for 28 d.
Abbreviations: lM, longissimus muscle; ST, semitendinosus; SQ, subcutaneous; 




















































Figure 4 effects of palmitoleic acid infusion on mean adipocyte size and distribution.
Notes: Mean adipocyte size (μm) (A) for both iM and SQ adipose tissues, and 
adipocyte size distribution (μm) (B) for iM adipose tissues by palmitoleic acid 
infusion level. iM adipocyte size was smaller (P,0.05) in palmitoleic acid infusion for 
dose level 10 mg/kg BW/d.
Abbreviations: lW, lipid weight; d, days; iM, intramuscular; SQ, subcutaneous; 
BW, body weight.
ST muscle) examined compared to the controls (Figure 6A). 
Protein levels of AMPKα1 did not differ (P.0.05) in the three 
tissues (liver, subcutaneous adipose, and ST muscle) of palmi-
toleic acid-treated group compared to controls (Figure 6B). 
Protein level of p-AMPKα1 and the ratio of p-AMPKα1 to 
AMPKα1 in all three tissues (liver, subcutaneous adipose, and 
ST muscle) were higher (P,0.05) for palmitoleic acid-treated 
group compared to controls (Figure 6C and D). Expression 
of other genes involved in glucose and insulin regulation 
(phosphoinositide-3-kinase, regulatory subunit 1 [alpha] 
[PI3KR1], insulin receptor [IR], v-akt murine thymoma viral 
oncogene homolog 1 [AKT1], and insulin receptor substrate 
1 [IRS1]) was unchanged with palmitoleic acid infusion. The 
interaction between palmitoleic acid infusion level and tissue 
(subcutaneous [SQ], semitendinosus [ST], and liver) was 
significant (P,0.05) for glucose transporter type 4 (GLUT4) 












































Figure 5 Fold-change in lipogenic gene expression for 10 mg c16:1/kg lW/d versus control (0 mg/kg BW/d) averaged over the three tissues (subcutaneous adipose tissue, 
ST muscle, and liver).
Notes: *P,0.05. **P,0.01.
Abbreviations: BW, body weight; lW, lipid weight; d, days; ST, semitendinosus; ScD, stearoyl-coa desaturase; FaSn, fatty acid synthase; acc, acetyl-coa carboxylase; 
elOVl5, fatty acid elongase-5; elOVl6, fatty acid elongase-6; cPT1a, carnitine palmitoyltransferase 1a; hSl, hormone-sensitive lipase; FaBP4, fatty acid binding protein 4.
C22. Green et al15 reported that ELOVL6 elongates c16–c18, 
whereas ELOVL5 elongates C16:1 cis-9–C18:1 cis-11 in rat 
insulinoma cell line. In this study, relative mRNA expression 
level of ELOVL6 was upregulated because of palmitoleic 
acid treatment (10 mg/kg LW/d) in intramuscular adipose 
tissues. The relative mRNA expression level of ELOVL5 
did not change with palmitoleic acid infusion. Results from 
our in vitro studies also showed that exogenous palmitoleic 
acid addition to bovine adipocytes increased cis-11 vac-
cenic acid to 50% or greater of total fatty acids and altered 
ELOVL6 mRNA expression with no change in ELOVL5.3,4 
These results would suggest that in ruminant species (ovine 
and bovine), ELOVL6 may be responsible for the elongation 
of palmitoleic acid to cis-11 vaccenic acid, differing from 
Green et al’s15 findings in rat cell culture.
Daily weight gain was reduced by 77% in the high-dose 
level of palmitoleic acid. Yang et al16 found that palmitoleic 
acid administered orally to rats decreased food intake in a 
dose–response manner, which was accompanied by increased 
circulating and mRNA expression of cholecystokinin levels, 
a satiety-related hormone. Overall, body composition did not 
differ with palmitoleic acid treatment and averaged about 
40% of total lipid. The sheep used in this study were obese 
and therefore, a short-term (28 days) treatment period would 
likely not be long enough to detect differences in overall body 
composition. Rates of lipolysis for sheep in a fed state are 
about 40% lower than rates of lipogenesis,17 and rates of sub-
cutaneous fat accretion are estimated at 0.0085 cm/d;18 there-
fore, it would take approximately 114 days or more to reduce 
subcutaneous fat thickness by 20%. However,  palmitoleic 
acid treatment did reduce intramuscular adipocyte size and 
total lipid content in the muscle tissues. Intramuscular fat is a 
late-developing fat depot,19 which may make it more suscep-
tible to short-term treatments prior to slaughter. Infusion of 
palmitoleic acid increased concentrations of palmitoleic and 
cis-11 vaccenic acids in all tissues. Because the palmitoleic 
acid response on total lipid was observed in the muscle, we 
further examined which fraction  (triacylglyceride, PhL, or 
FFA) these fatty acids were partitioned into. Palmitoleic and 
cis-11 vaccenic acids were predominately (90% or greater) 
located in the triacylglycerol fraction with only minor por-
tions in FFA or PhL fractions. Thus, it appears that exogenous 
palmitoleic acid is deposited in the intramuscular triacylg-
lycerol fraction in the muscle where it reduces adipocyte size 
through reductions in total lipid content. These reductions 
in intramuscular adipocyte size and lipid content are also 
accompanied by a reduction in circulating insulin levels and 
appear to restore insulin sensitivity.































































Figure 6 effects of palmitoleic acid infusion on gene expression and protein content 
of tissues.
Notes: Fold-change in glucose/insulin-related gene expression (A) for 10 mg 
c16:1/kg lW/d versus control (0 mg/kg BW/d) averaged over the three tissues 
(subcutaneous adipose tissues, ST muscle, and liver). Density of aMPKα1 protein 
density (B), paMPKα1 protein density (C), and ratio of paMPKα1 to aMPKα1 
for 10 mg c16:1/kg lW/d versus control (0 mg/kg BW/d) averaged over the three 
tissues (subcutaneous adipose tissues, ST muscle, and liver). *P,0.05.
Abbreviations: lW, lipid weight; d, days; BW, body weight; ST, semitendinosus; aMPK, 
protein kinase, aMP-activated, alpha 1 catalytic subunit, transcript variant 1; P13Kr1, 
phosphoinositide-3-kinase, regulatory subunit 1 (alpha); ir, insulin receptor; aKT1,v-akt 
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Figure 7 Palmitoleic acid infusion alters gene expression differentially by tissue.
Notes: Fold-change in gene expression for 10 mg c16:1/kg lW/d versus control 
(mg/kg lW/d) by tissue (subcutaneous adipose, liver, and ST muscle). The interaction 
between palmitoleic acid infusion and tissue (ST, SQ, liver) was significant (P,0.05) 
for glUT4 and cPT1b. *P,0.05. **P,0.01.
Abbreviations: lW, lipid weight; d, days; ST, semitendinosus; SQ, subcutaneous; 
glUT4, glucose transporter type 4; cPT1b, carnitine palmitoyltransferase 1b.
Research has shown that high levels of intramuscular lipid 
are negatively correlated to insulin sensitivity.20,21 Perseghin 
et al22 found through the use of nuclear magnetic resonance 
(NMR) spectroscopy that intramuscular triglyceride content 
of the soleus and plasma FFAs predicted whole body insulin 
sensitivity. Although the exact mechanism is not understood, 
it appears that skeletal muscle oxidation rates and/or the 
release of biologically active lipids or fatty acids that signal 
downstream molecules such as IRS1, protein kinase B/Akt, 
or protein tyrosine phosphatase 1B (PTP1B) are involved 
in restoring insulin sensitivity.23–25 In this study, infusion of 
palmitoleic acid reduced circulating insulin levels without 
altering circulating glucose levels. Previous research has 
shown that plasma glucose and insulin levels were elevated 
immediately after a single pulse dose of palmitoleic acid 
infusion in a dose–response manner.5 Insulin resistance, 
as determined using the HOMA calculator, is defined by 
a value of 2.71 or greater.26 At the beginning of this study, 
the HOMA-IR levels for sheep used in this study were at or 
above this level indicating insulin resistance. By the end of 
the 28-day study, HOMA-IR levels declined (P,0.05) to 1.42 
and 1.05 in the 5 mg/kg LW/d and 10 mg/kg LW/d palmitoleic 
acids, respectively. HOMA-IR levels in the controls (0 mg 
C16:1/kg LW/d) did not differ over the 28-day treatment 
period. These results indicate that palmitoleic acid treatment 
improved insulin resistance in obese sheep during a 28-day 
treatment period.





Relative mRNA expression of AMPKα1 was upregulated 
in subcutaneous adipose, ST muscle, and liver with palmi-
toleic acid infusion. Protein expression of p-AMPKα1 and 
the ratio of p-AMPKα1 to AMPKα1 were also higher in 
subcutaneous adipose, ST muscle, and liver with palmitoleic 
acid infusion compared to control. Expression of other genes 
involved in glucose/insulin regulation (IR, PI3KR1, AKT1, 
IRS) was unchanged with palmitoleic acid infusion in these 
tissues. Hoffman et al27 have shown that chromium supple-
mentation activates AMPK in insulin-dependent skeletal 
muscle cells. These authors propose that AMPK activity 
in skeletal muscle is critical to determining fuel used for 
energy in cells and could prevent or delay the onset of insu-
lin resistance. In a review by Coughlan et al,28 they suggest 
that activation of AMPK will improve insulin sensitivity. 
AMPK appears to play a role in regulating skeletal muscle 
glucose and fatty acid utilization.29,30 Locher et al31 reported 
higher levels of AMPK phosphorylation in dairy cows during 
early lactation when cows are typically in a negative energy 
balance. Lipolysis appears to induce AMPK phosphorylation 
in 3T3L1 adipocytes in vitro.32
Relative mRNA expression of GLUT4 and CPT1B 
showed a differential regulation depending on tissue. For the 
subcutaneous adipose and liver, palmitoleic acid upregulated 
GLUT4 and CPT1B mRNA levels. However, palmitoleic acid 
infusion downregulated GLUT4 and CPT1B mRNA levels in 
the ST muscle. The differential regulation of these genes sug-
gests a possible mechanism by which palmitoleic acid may 
exert tissue-specific effects on intramuscular adipocytes to 
reduce triacylglyceride content and their size. The results in 
the subcutaneous adipose tissue gene expression are similar 
to what we observe in bovine adipocytes in culture with 
increases in CPT1B and reductions in SCD1.3,4 However, 
the downregulation of CPT1B in the ST muscle would seem 
contrary to the results observed for reduced intramuscular 
adipocyte size and triacylglycerol content. Others33 have also 
observed a reduced oxidative capacity in mice with improved 
whole body glucose utilization and insulin-stimulated glucose 
uptake. Other factors, like reactive oxygen species produc-
tion in the mitochondria, may be more involved in insulin 
sensitivity.23,34,35 Knockout of the SCD1 gene in mice upregu-
lated lipid oxidation and downregulated lipogenic genes to 
protect them from diet-induced obesity.2 Previous research 
evaluating a pulse dose infusion of palmitoleic acid resulted 
in immediate elevations in circulating glucose and insulin that 
appeared to be related to glucose uptake into the peripheral 
cells. This longer term infusion study with palmitoleic acid 
shows that GLUT4 mRNA expression is reduced in skeletal 
muscle, and indicates that this may be related to changes in 
insulin sensitivity when administered for 28 days. Additional 
research is needed to examine the mechanism of action as 
to how exogenous palmitoleic acid reduces intramuscular 
adipocyte size and triacylglyceride content to restore insulin 
sensitivity.
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